Abstract
Bioactivity guided separation of combined n-hexane and chloroform extracts of Oplismenus burmannii resulted in the isolation and characterization of five new glycoglycerolipids, (2S)-1,2,6’-tri- O-hexadecanoyl-3-O-β-D-galactopyranosyl glycerol (1a), (2S)-1,2,6’-tri-O-[(9Z,12Z)-octadeca-9,12- dienoyl]-3-O-β-D-galactopyranosyl glycerol (1b), (2S)-1,6’-di-O-[(9Z,12Z)-octadeca-9,12-dienoyl]-3- O-β-D-galactopyranosyl glycerol (2b), (2S)-1,6’-di-O-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]-3-O-β-D-galactopyranosyl glycerol (2c), and (2S)-1,2-di-O-[(9Z,12Z)-octadeca-9,12-dienoyl]-3-O-(6- sulpho-α-D)-quinovopyranosyl glycerol (3b) along with five known glycoglycerolipids (1c, 2a, 3a, 3c and 4), a cerebroside (5), three monoacylglycerols (6a-c) and α-linoleic acid (7). The isolated compounds, 1-5 were in-vitro tested for their antihyperglycemic potential in terms of increase in 2-deoxyglucose uptake in L6-GLUT4myc myotube cells. The results showed that compounds, 1-5 were showing 1.52 (P<0.05), 1.50 (P<0.05), 1.28, 1.49 (P<0.05) and 1.50 (P<0.05) fold increase in the glucose uptake at concentration of 10 μg/mL and 1.71 (P<0.001), 1.74 (P<0.001), 1.50 (P<0.05), 1.76 (P<0.001) and 1.74 (P<0.001) fold increase in the glucose uptake at concentration of 25 μg/mL respectively. However, standard drug Rosiglitazone increases the glucose uptake by 1.59 fold at the concentration of 10μM. Further work on optimization of the anti-diabetic lead is under progress.
Keywords: Cerebroside, Glucose uptake, Glycoglycerolipids, L6-GLUT4myc myotube cells, Rosiglitazone.
Current Topics in Medicinal Chemistry
Title:Glycolipids: Isolated from Oplismenus burmannii Induce Glucose Uptake in L6-GLUT4myc Myotube Cells
Volume: 15 Issue: 11
Author(s): Surjeet Verma, Deepti Arha, Akhilesh Kumar Tamrakar and Santosh Kumar Srivastava
Affiliation:
Keywords: Cerebroside, Glucose uptake, Glycoglycerolipids, L6-GLUT4myc myotube cells, Rosiglitazone.
Abstract: Bioactivity guided separation of combined n-hexane and chloroform extracts of Oplismenus burmannii resulted in the isolation and characterization of five new glycoglycerolipids, (2S)-1,2,6’-tri- O-hexadecanoyl-3-O-β-D-galactopyranosyl glycerol (1a), (2S)-1,2,6’-tri-O-[(9Z,12Z)-octadeca-9,12- dienoyl]-3-O-β-D-galactopyranosyl glycerol (1b), (2S)-1,6’-di-O-[(9Z,12Z)-octadeca-9,12-dienoyl]-3- O-β-D-galactopyranosyl glycerol (2b), (2S)-1,6’-di-O-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]-3-O-β-D-galactopyranosyl glycerol (2c), and (2S)-1,2-di-O-[(9Z,12Z)-octadeca-9,12-dienoyl]-3-O-(6- sulpho-α-D)-quinovopyranosyl glycerol (3b) along with five known glycoglycerolipids (1c, 2a, 3a, 3c and 4), a cerebroside (5), three monoacylglycerols (6a-c) and α-linoleic acid (7). The isolated compounds, 1-5 were in-vitro tested for their antihyperglycemic potential in terms of increase in 2-deoxyglucose uptake in L6-GLUT4myc myotube cells. The results showed that compounds, 1-5 were showing 1.52 (P<0.05), 1.50 (P<0.05), 1.28, 1.49 (P<0.05) and 1.50 (P<0.05) fold increase in the glucose uptake at concentration of 10 μg/mL and 1.71 (P<0.001), 1.74 (P<0.001), 1.50 (P<0.05), 1.76 (P<0.001) and 1.74 (P<0.001) fold increase in the glucose uptake at concentration of 25 μg/mL respectively. However, standard drug Rosiglitazone increases the glucose uptake by 1.59 fold at the concentration of 10μM. Further work on optimization of the anti-diabetic lead is under progress.
Export Options
About this article
Cite this article as:
Verma Surjeet, Arha Deepti, Tamrakar Kumar Akhilesh and Srivastava Kumar Santosh, Glycolipids: Isolated from Oplismenus burmannii Induce Glucose Uptake in L6-GLUT4myc Myotube Cells, Current Topics in Medicinal Chemistry 2015; 15 (11) . https://dx.doi.org/10.2174/1568026615666150317223112
DOI https://dx.doi.org/10.2174/1568026615666150317223112 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Profile of SSRIs and SNRIs in the Treatment of Eating Disorders
Current Clinical Pharmacology Baroreflex Function: Determinants in Healthy Subjects and Disturbances in Diabetes, Obesity and Metabolic Syndrome
Current Diabetes Reviews Metabolic Enzymes of Helminth Parasites: Potential as Drug Targets
Current Protein & Peptide Science Neurobiological Basis and Pharmacologic Treatment of Social Impairment in Autism Spectrum Disorders
Current Psychopharmacology Medical Treatment of Critical Limb Ischemia: Current State and Future Directions
Current Vascular Pharmacology Hypertriglyceridemia: An Infrequent, Difficult-to-predict, Severe Metabolic and Vascular Problem Associated with Estrogen Administration
Current Vascular Pharmacology Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Impact of Diabetes on Vasculature: Focus on Nervous System
Current Diabetes Reviews Glucose Transport and Metabolism in Sertoli Cell: Relevance for Male Fertility
Current Chemical Biology Dissecting Insulin Signaling Pathways: Individualised Therapeutic Targets for Diagnosis and Treatment of Insulin Resistant States
Endocrine, Metabolic & Immune Disorders - Drug Targets The Development and Progression of Atherosclerosis: Evidence supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets Cutoff Values of D-Dimer and FDP in Plasma for the Diagnosis of Thrombosis
Vascular Disease Prevention (Discontinued) An Evolution of Bilirubin Physiology and Analysis
Current Signal Transduction Therapy Diabetes and Pancreas: Why So Difficult? Potential Mechanisms of Elevated Serum Pancreatic Enzymes
Current Medicinal Chemistry Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) Targeting JAK3 Tyrosine Kinase-Linked Signal Transduction Pathways with Rationally-Designed Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Diabetes, Cancer and Treatment – A Mini-Review
Current Drug Safety Red Wine Consumption and Prevention of Atherosclerosis: An In Vitro Model Using Human Peripheral Blood Mononuclear Cells
Current Pharmaceutical Design Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets Advanced Diabetes Care: Three Levels of Prediction, Prevention & Personalized Treatment
Current Diabetes Reviews